neoag
Neoantigen × AI
Daily research signal
FIELD MAP / MODALITY

Viral-vector vaccines

Engineered viral vectors (adeno, vaccinia/MVA, lentivirus, AAV) that deliver neoantigen payloads — including Nouscom's and Transgene's programs.

Topic4 items2026-05-29 – 2026-06-08
Modalities
Peptide vaccines64TCR & T-cell receptor34mRNA vaccines31Dendritic-cell vaccines25Shared & off-the-shelf16DNA vaccines11Lipid nanoparticles5Viral-vector vaccines4Oncolytic viruses1
01
Clinical

Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

Centre Georges Francois Leclerc is planning a Phase 1 study for ODI-2001, a personalized DNA neoantigen vaccine combined with an MVA viral adjuvant and ipilimumab. The trial targets metastatic or locally advanced colorectal and pancreatic cancers, beginning with dose escalation to determine the maximum tolerated dose before expanding to assess progression-free survival.

Pancreatic cancerColorectal cancer
clinicaltrials · brief 2026-06-08 · published 2026-05-14
02
Clinical

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis - Nature

A Nature study shows that oncolytic adenovirus delivery of neoantigens can sensitize low-mutation tumors to anti-PD-1 therapy and prevent metastasis. This offers a potential solution for 'cold' tumors with low neoantigen burden, leveraging viral vectors to enhance antigen presentation and immune infiltration.

Oncolytic viruses
news · brief 2026-06-04 · published 2025-12-23
03
Clinical

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results - Nature

Interim results from a Phase 1 trial of an individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine show activity in advanced metastatic solid tumors. This highlights the diversification of delivery vectors beyond standard mRNA, potentially offering improved immunogenicity or manufacturing advantages.

mRNA vaccines
news · brief 2026-06-01 · published 2022-08-15
04
Clinical

Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer

Centre Georges Francois Leclerc is initiating a Phase I study of ODI-2001, a personalized DNA neoantigen vaccine combined with a Modified Vaccinia Ankara adjuvant and ipilimumab. The trial targets metastatic or locally advanced colon and pancreatic cancers, starting with dose escalation to determine the maximum tolerated dose.

Pancreatic cancerColorectal cancer
clinicaltrials · brief 2026-05-29 · published 2026-05-14
Where nextAll topicsToday’s briefTrials tracker